# EDGAR Filing Document

**Accession Number:** 0001642380
**File Stem:** 0001641172-25-017590
**Filing Date:** 2025-7
**Character Count:** 8195
**Document Hash:** 4491477cfcd70c83cc7812529ff0e464
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001641172-25-017590.hdr.sgml**: 20250702

**ACCESSION NUMBER**: 0001641172-25-017590

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 12

**CONFORMED PERIOD OF REPORT**: 20250627

**ITEM INFORMATION**: Submission of Matters to a Vote of Security Holders

**FILED AS OF DATE**: 20250702

**DATE AS OF CHANGE**: 20250702

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Insight Molecular Diagnostics Inc.
- **CENTRAL INDEX KEY:** 0001642380
- **STANDARD INDUSTRIAL CLASSIFICATION:** IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 271041563
- **STATE OF INCORPORATION:** CA
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-37648
- **FILM NUMBER:** 251102309

**BUSINESS ADDRESS:**
- **STREET 1:** 2 INTERNATIONAL PLAZA DR., SUITE 510
- **CITY:** NASHVILLE
- **STATE:** TN
- **ZIP:** 37217
- **BUSINESS PHONE:** 949-409-7600

**MAIL ADDRESS:**
- **STREET 1:** 2 INTERNATIONAL PLAZA DR., SUITE 510
- **CITY:** NASHVILLE
- **STATE:** TN
- **ZIP:** 37217

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Oncocyte Corp
- **DATE OF NAME CHANGE:** 20210920

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** OncoCyte Corp
- **DATE OF NAME CHANGE:** 20200213

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Oncocyte Corp
- **DATE OF NAME CHANGE:** 20200205

?xml version='1.0' encoding='ASCII'?

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 8-K**

Current Report

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): **June 27, 2025**

**Insight Molecular Diagnostics Inc.**

(Exact name of Registrant as specified in its charter)

---

| | | |
|:---|:---|:---|
| **California** | **1-37648** | **27-1041563** |
| (State or other jurisdiction <br> of incorporation) | (Commission <br> File No.) | (IRS Employer <br> Identification No.) |

---

**2 International Plaza Dr., Suite 510**

**Nashville, Tennessee 37217**

(Address of principal executive offices) (Zip code)

**(949) 409-7600**

Registrant's telephone number, including area code

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities Registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered |
| Common stock, no par value | IMDX | The Nasdaq Stock Market LLC |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

**Item 5.07. Submission of Matters to a Vote of Security Holders.**

**General**

On June 27, 2025, Insight Molecular Diagnostics Inc. (the "Company") held its 2025 Annual Meeting of Shareholders (the "Annual Meeting") virtually via live webcast at *https://web.lumiconnect.com/259974801*. Present at the Annual Meeting virtually or by proxy were holders of 21,008,960 shares of common stock of the Company, which represented 73.46% of the voting power of all shares of common stock of the Company as of May 12, 2025, the record date for the Annual Meeting.

**Proposals**

The shareholders of the Company voted on the following proposals at the Annual Meeting, as more fully described in the definitive proxy statement on Schedule 14A relating to the Annual Meeting, which was originally filed with the Securities and Exchange Commission on May 14, 2025 (the "Proxy Statement"):

&nbsp;&nbsp;&nbsp;&nbsp;1. To
 elect the following four (4) director nominees, each to serve until the 2026 annual meeting
 of shareholders and until his or her successor has been elected and qualified, or until his
 or her earlier death, resignation, or removal: Joshua Riggs, Andrew Arno, Andrew J. Last
 and Louis E. Silverman;

&nbsp;&nbsp;&nbsp;&nbsp;2. To
 ratify the appointment of CBIZ CPAs P.C. as the Company's independent registered public
 accounting firm for the year ending December 31, 2025

&nbsp;&nbsp;&nbsp;&nbsp;3. To
 approve, on a non-binding advisory basis, the Company's named executive officer compensation
 for the year ended December 31, 2024; and

&nbsp;&nbsp;&nbsp;&nbsp;4. To
 approve an amendment to the Company's Amended and Restated 2018 Equity Incentive Plan
 to increase the total number of shares of the Company's common stock authorized for
 issuance under such plan by 1,500,000, to a total of 3,800,000 shares.

**Voting Results**

The final voting results for each of these proposals at the Annual Meeting are detailed below.

**1. Election of Directors**

---

| | | | | |
|:---|:---|:---|:---|:---|
| | | **Shares Voted** | **Shares Voted** | **Shares Voted** |
| <br>**Director Nominee** |<br>**For** | **Against** | **Abstained** | **Broker Non-Votes** |
| Joshua Riggs | 18094181 | 6225 | 3890 | 2904664 |
| Andrew Arno | 18033599 | 66567 | 4130 | 2904664 |
| Andrew J. Last | 18041724 | 58642 | 3930 | 2904664 |
| Louis E. Silverman | 18035578 | 64816 | 3902 | 2904664 |

---

Based on the votes set forth above, each director nominee was duly elected to serve until the 2026 annual meeting of shareholders and until his or her successor has been elected and qualified, or until his or her earlier death, resignation, or removal.

**2. Ratification of Appointment of Accounting Firm**

---

| | | | |
|:---|:---|:---|:---|
| **Shares Voted** | **Shares Voted** | **Shares Voted** | **Shares Voted** |
| **For** | **Against** | **Abstained** | **Broker Non-Votes** |
| 20986994 | 4951 | 17015 | 0 |

---

Based on the votes set forth above, the shareholders ratified the appointment of CBIZ CPAs P.C. as the Company's independent registered public accounting firm for the year ending December 31, 2025.

**3. Say On Pay Proposal**

---

| | | | |
|:---|:---|:---|:---|
| **Shares Voted** | **Shares Voted** | **Shares Voted** | **Shares Voted** |
| **For** | **Against** | **Abstained** | **Broker Non-Votes** |
| 18063639 | 28647 | 12010 | 2904664 |

---

Based on the votes set forth above, the shareholders approved, on a non-binding advisory basis, the Company's named executive officer compensation for the year ended December 31, 2024.

**4. Approval of Amendment to Amended and Restated Incentive Plan**

---

| | | | |
|:---|:---|:---|:---|
| **Shares Voted** | **Shares Voted** | **Shares Voted** | **Shares Voted** |
| **For** | **Against** | **Abstained** | **Broker Non-Votes** |
| 17958519 | 140508 | 5269 | 2904664 |

---

Based on the votes set forth above, the shareholders approved the amendment to the Company's Amended and Restated 2018 Equity Incentive Plan to increase the total number of shares of the Company's common stock authorized for issuance under such plan by 1,500,000, to a total of 3,800,000 shares.

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | | |
|:---|:---|:---|
|  | **INSIGHT MOLECULAR DIAGNOSTICS INC.** | **INSIGHT MOLECULAR DIAGNOSTICS INC.** |
| Date: July 2, 2025 | By: | */s/ Peter Hong* |
|  | Name: | Peter Hong |
|  | Title: | Vice President, General Counsel |

---